

Please type a plus sign (+) inside this box →



PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 1 of 1

Complete If Known

Application Number	unassigned
Filing Date	New Application
First Named Inventor	ARZENO, et al.
Group Art Unit	unassigned
Examiner Name	unassigned
Attorney Docket Number	R0096B-REG

U.S. PATENT DOCUMENTS

Examiner Initials *	Cite No. ¹	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code ² (if known)			
	A1	5,620,981		Blankley, et al.	15-Apr-1997	
	A2	5,733,914		Blankley, et al.	31-Mar-1998	
	A3	5,945,422		Doherty, et al.	31-Aug-1999	

FOREIGN PATENT DOCUMENTS

Examiner Initials *	Cite No. ¹	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ₆
		Office ³	Number ⁴	Kind Code ⁵ (if known)				
	B1	WO	96/34867	A1	PCT application; Warner-Lambert Co.	07-Nov-1996		

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	C1	BOEHM and ADAMS, "New inhibitors of p38 kinase," <u>Expert Opinion on Therapeutic Patents</u> , Vol 10:1 (2000), pp 25-37	
	C2	TRUMPP-KALLMEYER, et al., "Development of a Binding Model to Protein Tyrosine Kinases for Substituted Pyrido[2,3-d]pyrimidine Inhibitors," <u>J. Medicinal Chemistry</u> , Vol. 41 (1998), pp 1752-1763	
	C3	KLUTCHKO, et al., "2-Substituted Aminopyrido[2,3-d]pyrimidin-7(8H)-ones. Structure-Activity Relationships Against Selected Tyrosine Kinases and in Vitro and in Vivo Anticancer Activity," <u>J. Medicinal Chemistry</u> , Vol. 41 (1998), pp 3276-3292	
	C4	BOSCHELLI, et al., "Synthesis and Tyrosine Kinase Inhibitory Activity of a Series of 2-Amino-8H-pyrido[2,3-d]pyrimidines: Identification of Potent Selective Platelet-Derived Growth Factor Receptor Tyrosine Kinase Inhibitors," <u>J. Medicinal Chemistry</u> , Vol. 41 (1998), pp 4365-4377	

Examiner Signature

Date Considered

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Doc. #114985

LIST OF REFERENCE(S) CITED				ATTY. DOCKET NO. R0096B-REG		SERIAL NO. 09/943,338	
				APPLICANT(S) Arzeno, et al.			
				FILING DATE August 30, 2001		GROUP 1624	
U.S. PATENT DOCUMENTS							
Exam Initial	Ref. #	Document #	Date	Name	Class/ Subclass	Filing Date	
FOREIGN PATENT DOCUMENTS							
	Ref.#	Document #	Date	Country; Assignee	Translation		
					Yes	No	
		WO 96/34867	07-Nov-96	PCT; Warner-Lambert Company			
		WO 02/18380	07-Mar-02	PCT; F. Hoffmann-LaRoche AG			
OTHER DOCUMENTS							
EXAMINER				DATE CONSIDERED			
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.							